UPDATE | November 12, 2026
A streamlined cell line development platform for complex molecules: Integrating vector strategy with high-throughput quality monitoring
Developing cell lines for complex molecules such as bispecific antibodies (bsAbs) and fusion proteins requires precise control of multi-chain assembly to achieve both high productivity and desired product quality attributes.
This poster presents Samsung Biologics' streamlined cell line development (CLD) platform, integrating molecule-specific vector design with early-stage, high-throughput quality monitoring to support the selection of high-performing clones.
Key highlights include:
Optimized vector ratios to maximize heterodimer fidelity alongside high volumetric productivity
Early high-throughput screening of glycoprofiles and binding kinetics
Early elimination of sub-optimal clones through strong orthogonal correlation to high-performance analytical methods
Discover how proactive screening can streamline cell line development and help mitigate downstream biomanufacturing risks.
Developing cell lines for complex molecules such as bispecific antibodies (bsAbs) and fusion proteins requires precise control of multi-chain assembly to achieve both high productivity and desired product quality attributes.
This poster presents Samsung Biologics' streamlined cell line development (CLD) platform, integrating molecule-specific vector design with early-stage, high-throughput quality monitoring to support the selection of high-performing clones.
Key highlights include:
- Optimized vector ratios to maximize heterodimer fidelity alongside high volumetric productivity
- Early high-throughput screening of glycoprofiles and binding kinetics
- Early elimination of sub-optimal clones through strong orthogonal correlation to high-performance analytical methods
Discover how proactive screening can streamline cell line development and help mitigate downstream biomanufacturing risks.
Related Content